-
公开(公告)号：WO2021224680A1
公开(公告)日：2021-11-11
申请号：PCT/IB2021/000304
申请日：2021-05-06
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： KAMEL, Amin, Mohamed , BOWLIN, Stephen, Uriah
Abstract: Compounds that are mammalian metabolites of an agonist of G-protein-coupled receptor 1.39 (GPR139), intermediates used in the synthesis of such metabolites, pharmaceutical compositions comprising such metabolites, and the use of such metabolites as biomarkers and agents in the treatment of schizophrenia, for example, negative and/or cognitive symptoms of schizophrenia, disorders associated with social and cognitive dysfunction, as well as several other disorders related to modulated of GPR139.
-
公开(公告)号：WO2021224680A8
公开(公告)日：2021-11-11
申请号：PCT/IB2021/000304
申请日：2021-05-06
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： BOWLIN, Stephen, Uriah , KAMEL, Amin, Mohamed
IPC: C07D253/08 , A61P25/00 , A61K31/53 , C07C1/00 , C07H1/00 , C07K1/00 , C07C201/00 , C07H17/02 , C07K5/0606
Abstract: Compounds that are mammalian metabolites of an agonist of G-protein-coupled receptor 1.39 (GPR139), intermediates used in the synthesis of such metabolites, pharmaceutical compositions comprising such metabolites, and the use of such metabolites as biomarkers and agents in the treatment of schizophrenia, for example, negative and/or cognitive symptoms of schizophrenia, disorders associated with social and cognitive dysfunction, as well as several other disorders related to modulated of GPR139.
-
公开(公告)号：EP4146635A1
公开(公告)日：2023-03-15
申请号：EP21734917.4
申请日：2021-05-06
Applicant: Takeda Pharmaceutical Company Limited
Inventor： BOWLIN, Stephen, Uriah , KAMEL, Amin, Mohamed
-
-
Search Results
3
records
(took 0.026 seconds)
